Evaluation of Prolidase in Obstructive Sleep Apnea Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

74 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-07-01

Study Completion Date

2018-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obstructive sleep apnea (OSA) is a highly prevalent breathing disorder in sleep. We have aimed to evaluate the relationship between OSA and prolidase activity, the oxidative stress index (OSI), total antioxidative capacity (TAC), and total oxidative capacity (TOC) and the relationship between carotid intima media thickness (CIMT).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NADPH Oxidase Polymorphisms in Obstructive Sleep Apnea Syndrome (OSAS)

NCT01141829

Sleep Apnea Syndrome Oxidative Stress Single Nucleotide Polymorphism

UNKNOWN

Inflammatory Mediators in Obstructive Sleep Apnoea Syndrome; Mechanisms of Production and the Effect of Long Term Antioxidants Administration

NCT01188005

Obstructive Sleep Apnea Syndrome

UNKNOWN NA

XOR Levels in OSA Patients (XOR-OSA)

NCT06554496

Obstructive Sleep Apnea

RECRUITING NA

Physical Status of OSA Patients

NCT05051514

Obstructive Sleep Apnea Syndrome

COMPLETED

Predictors of OSA in Patients With COPD

NCT05605431

OSA COPD

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was approved by the local ethics committee in accordance with the Helsinki Declaration. Written informed consent was received from the OSAS Subjects patients and control subjects before enrolment in the study. The patient and control cohorts were recruited from the Pulmonary Medicine Department, Medical Faculty, Yuzuncu Yıl University. Blood samples were analysed at the Biochemistry Laboratory of Harran University Medical Faculty TAC and TOS levels were measured by using an automated measurement method. TAC measurement method involves the production of a potent biological hydroxyl radical. Ferrous ion solution is mixed with hydrogen peroxide. Thus, it is possible to measure the anti-oxidative effect of the sample against the potent free radical reactions initiated by the production of the hydroxyl radical. TOS method is based on the oxidation of ferrous ion to ferric ion in the presence of various oxidant species in acidic medium and the measurement of the ferric ion by xylenol orange. mmol Trolox equivalent (equiv)/L, mmol H2O2 /L and mg/dL, respectively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obstructive Sleep-Apnea Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group OSAS

We included 56 with OSAS \[13 subjects 23.2% mild, 19 subjects 33.9% moderate, 24 subjects 42.8% severe

No interventions assigned to this group

control group

simple snoring

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients were diagnosed with OSA after night polysomnography (PSG).
* Patients were enrolled in the study following receipt of their written informed consent.

Exclusion Criteria

* Patients had ischaemic cardiovascular diseases,
* Patients had chronic obstructive pulmonary diseases,
* Patients had ischaemic cerebral diseases,
* Patients had chronic inflammatory diseases,
* Patients had chronic and acute systemic infections.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No